RELEASE: Philips joins EUCAIM to advance precision medicine in cancer patients

(Information sent by the signatory company).

RELEASE: Philips joins EUCAIM to advance precision medicine in cancer patients

(Information sent by the signatory company)

AMSTERDAM, 2 Feb.

Philips has announced its active membership in the new consortium of the European Federation for Cancer Imaging (EUCAIM), a project within the European Cancer Imaging Initiative launched by the European Commission at an event held in Brussels two weeks before World Cancer Day. Cancer 2023.

In response to the need for researchers to access cancer data globally and with the quality necessary to develop new solutions to help detect, diagnose and treat cancer, particularly all those based on artificial intelligence (AI), the Initiative European Cancer Imaging will work to create a digital infrastructure connecting cancer imaging databases and resources across the EU while ensuring adherence to strict ethics, trust, security and data protection standards.

Within this Initiative, the EUCAIM project will focus on designing and deploying a cancer imaging diagnostic data infrastructure, and the resulting atlas will be made available to the second key project of this initiative: the Center for Experimentation and Testing of Artificial Intelligence for Health (TEF-Health), which will allow subject matter experts and other partners to test AI-based solutions for cancer treatment using real data. It will also provide a platform for European citizens to have the possibility to donate their data to cancer research.

"The European Cancer Imaging Initiative will provide vital information for the next generation of cancer diagnosis and treatment and will help us make screening more accurate, timely and accessible. It is a key example of how we invest in and make the most of the potential of innovative digital solutions within the framework of the European Plan 'Beating Cancer' to change the reality of patients and their families", declared Stella Kyriakides, European Commissioner for Health and Food Safety at the presentation of the European Imaging Initiative for Cancer.

"We at Philips very much welcome this initiative as it provides access to oncology data and also an excellent opportunity to engage and collaborate with this community. This will help develop AI-powered solutions derived from this data and validate them with clinical partners and partners. such as the Hospital La Fe in Valencia or the Charité in Berlin.This initiative has an immediate application in innovations in cancer, since these are based on longitudinal patient data, as well as a wide set of them, to guarantee AI solutions that are adopted in clinical practice," said Tina Manoharan, Vice President of Data, AI and Digital Innovation at Philips.

Meeting the needs of expanded screening

One of the objectives of the European 'Beating Cancer' Plan is to guarantee that 90% of the EU population that meets the requirements to undergo a screening for breast, cervical or colorectal cancer can receive it in the year 2025, which This will result in a considerable increase in the volume of images from screening, in greater precision diagnosis and personalized treatment of detected cases. AI is widely seen as a powerful tool that could help radiologists cope with the increased workload. Combining AI with deep clinical insight, Philips is already creating solutions that integrate with, accelerate clinical workflows and provide clinicians with greater clarity at every stage of the cancer care journey.

For example, MRCAT Brain software uses trained AI models to capture the information needed to accurately and efficiently generate each patient's radiation therapy plan in a single, rapid MRI scan, without the need for a more time-consuming CT scanner. time and resources, and the subsequent joint registration of CT-MR images. Philips is currently collaborating with the Leiden University Medical Center in the Netherlands, which recently benefited from a €2 million grant from the Dutch Research Council (NWO), to develop new innovative AI solutions to accelerate and further enhance MR examinations with the goal of reducing scan times to less than five minutes and reconstructing detailed images despite movement of the patient or internal organs.

"By automating and speeding up routine imaging tasks, our AI-powered solutions simplify workflows and logistics, leaving clinicians more time to focus on their patients' needs. At the same time, our reconstruction tools AI-based imaging, quantitative analysis, and data integration enable oncologists to make better-informed decisions about diagnosis, therapy planning, treatment, and follow-up to provide their patients with the precise, personalized cancer care they deserve." says Reema Poddar, executive vice president of Clinical and Diagnostic Informatics at Philips.

AI-based solutions

Intelligent imaging solutions and clinical informatics solutions from Philips combine data from radiology, pathology, genomics, and electronic health record systems to provide a comprehensive, multiple view of each patient's cancer status, through plug-ins such as the multimodal tumor tracking, spectral tumor tracking, and CT virtual colonoscopy to aid decision-making.

The solution offers an additional layer of information access and management that includes clinical pathways, genomic computing, clinical reports, and comparison with Dana-Farber Cancer Institute clinical trials.

Philips demonstrates its commitment to the campaign

During the European Congress of Radiology Philips will present its latest intelligent AI-based technologies that help generate meaningful insights and improve clinical confidence and patient outcomes. Join Philips in person at the ECR or virtually through the Philips interactive radiology experience and follow @PhilipsLiveFrom for updates during the event.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHI) is a leading healthcare technology company focused on improving people's health and well-being, and facilitating better outcomes across the health cycle, from habits health and prevention, to diagnosis, treatment and home care. Philips draws on its advanced technology and in-depth clinical and consumer insights to offer integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as consumer health and home care. Philips has recorded sales of €17.8 billion in 2022 and employs approximately 77,000 employees, with business operations and services in more than 100 countries. All news about Philips can be found in our news center.

Issuer: Philips

Contact: César García Requena, Brand

NEXT NEWS